Renew Revenue and Competitors
Estimated Revenue & Valuation
- Renew's estimated annual revenue is currently $13.4M per year.
- Renew's estimated revenue per employee is $243,000
Employee Data
- Renew has 55 Employees.
- Renew grew their employee count by 0% last year.
Renew's People
Name | Title | Email/Phone |
---|---|---|
1 | Assistant Manager | Reveal Email/Phone |
2 | DGM wind power projects | Reveal Email/Phone |
Renew Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.3M | 156 | -3% | N/A | N/A |
#2 | $148.5M | 440 | N/A | N/A | N/A |
#3 | $124.2M | 368 | 46% | N/A | N/A |
#4 | $545.1M | 1442 | 17% | N/A | N/A |
#5 | $29.2M | 108 | 6% | N/A | N/A |
#6 | $12.9M | 53 | N/A | N/A | N/A |
#7 | $1125.1M | 2914 | 6% | $20.4M | N/A |
#8 | $15.3M | 63 | 15% | N/A | N/A |
#9 | $8.9M | 41 | 5% | N/A | N/A |
#10 | $4.3M | 23 | -15% | N/A | N/A |
What Is Renew?
The current prescription drug system is complex, inefficient, and built around misaligned incentives. We want to reimagine medication management from the ground up, with a focus on health outcomes over profits. We believe every prescription should be affordable, accessible, and adjusted to achieve maximal clinical benefit. To do so, we are building a modern technology platform that will anchor a highly differentiated approach to pharmacy benefits. This technology will power an innovative set of clinical services and exceptional member experience, which together can improve access, increase adherence, and ensure that members maximize the clinical benefit they receive from medications.
keywords:N/AN/A
Total Funding
55
Number of Employees
$13.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10.1M | 55 | 10% | N/A |
#2 | $6.2M | 55 | 2% | $7.3M |
#3 | $7.6M | 56 | 0% | N/A |
#4 | $8.7M | 56 | -29% | N/A |
#5 | $10.3M | 56 | -18% | N/A |